Xu ZZ - Search Results

1

The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment.

Xia ZG, Xu ZZ, Zhao WL, Zhao SQ, Ding F, Chen Y, Chen QS, Zheng Y, Zhu Q, Hu JP, Shen ZX, Li JM. Xia ZG, et al. Among authors: xu zz. Ann Hematol. 2010 Feb;89(2):171-7. doi: 10.1007/s00277-009-0799-2. Epub 2009 Aug 11. Ann Hematol. 2010. PMID: 19669764

2

Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006.

Wang AH, Wang YY, Yao Y, Xu ZZ, Zhou L, Wang L, Zhang L, Chen Y, Shen ZX, Hu J, Li JM. Wang AH, et al. Among authors: xu zz. J Exp Clin Cancer Res. 2010 Mar 3;29(1):20. doi: 10.1186/1756-9966-29-20. J Exp Clin Cancer Res. 2010. PMID: 20199658 Free PMC article.

3

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.

Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM. Xu ZZ, et al. Ann Hematol. 2013 Oct;92(10):1351-8. doi: 10.1007/s00277-013-1770-9. Epub 2013 May 2. Ann Hematol. 2013. PMID: 23636313

4

Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.

Xu ZZ, Wang WF, Fu WB, Wang AH, Liu ZY, Chen LY, Guo P, Li JM. Xu ZZ, et al. Leuk Lymphoma. 2014 May;55(5):1151-7. doi: 10.3109/10428194.2013.823492. Epub 2013 Aug 28. Leuk Lymphoma. 2014. PMID: 23841505

5

BAFF level increased in patients with autoimmune hemolytic anemia.

Zhao YB, Li JM, Wei BW, Xu ZZ. Zhao YB, et al. Among authors: xu zz. Int J Clin Exp Med. 2015 Mar 15;8(3):3876-82. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26064287 Free PMC article.

6

Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma.

Xu ZZ, Fu WB, Jin Z, Guo P, Wang WF, Li JM. Xu ZZ, et al. Leuk Lymphoma. 2016;57(4):888-98. doi: 10.3109/10428194.2015.1061127. Epub 2015 Nov 1. Leuk Lymphoma. 2016. PMID: 26415087

7

Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.

Jin Z, Qing K, Ouyang Y, Liu Z, Wang W, Li X, Xu Z, Li J. Jin Z, et al. J Exp Clin Cancer Res. 2016 Mar 24;35:52. doi: 10.1186/s13046-016-0327-x. J Exp Clin Cancer Res. 2016. PMID: 27009084 Free PMC article.

8

Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma.

Qing K, Jin Z, Fu W, Wang W, Liu Z, Li X, Xu Z, Li J. Qing K, et al. J Hematol Oncol. 2016 Aug 23;9(1):72. doi: 10.1186/s13045-016-0303-0. J Hematol Oncol. 2016. PMID: 27554093 Free PMC article.

9

HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells.

Wang WF, Yan L, Liu Z, Liu LX, Lin J, Liu ZY, Chen XP, Zhang W, Xu ZZ, Shi T, Li JM, Zhao YL, Meng G, Xia Y, Li JY, Zhu J. Wang WF, et al. Among authors: xu zz. Nat Commun. 2017 Aug 25;8(1):363. doi: 10.1038/s41467-017-00476-w. Nat Commun. 2017. PMID: 28842558 Free PMC article.

10

Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.

Xu ZZ, Shen JK, Zhao SQ, Li JM. Xu ZZ, et al. Leuk Lymphoma. 2018 Jun;59(6):1451-1460. doi: 10.1080/10428194.2017.1379077. Epub 2017 Sep 27. Leuk Lymphoma. 2018. PMID: 28952842

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

374 results

Search Page

Filters